Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Short interest in Hims & Hers Health Inc rose to a record high, even as shares surged following strong first-quarter results.

We recently published an article titled These 10 Stocks Moved the Market This Week, Here’s Why. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands ...

NEW YORK (Reuters) -Health and wellness companies are embracing weight-loss drugs and building offerings around them in an ...

The weight-loss drug revolution is reshaping the health and wellness industry, forcing companies to adapt or face the same ...

Hims & Hers continues to deliver strong revenue growth. Meanwhile, the company surprised investors by offering a long-term ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Just today, this drug became more widely available. Some product is now facing a recall following an apparent storage error.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...